Alliance Global downgraded Aptose Biosciences (APTOF) to Neutral from Buy with a C$2.41 price target The firm does not expect better offer than the Hanmi tender.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APTOF:
- Aptose Biosciences to be Acquired by Hanmi Pharmaceutical
- Aptose Biosciences Reports Financial Challenges in Q3 2025
- Aptose Biosciences Reports Promising Results in AML Therapy Trials
- Aptose Biosciences’ TUSCANY Study Highlighted at ASH 2025
- Aptose Biosciences’ Tuspetinib Study: A Potential Game-Changer in Leukemia Treatment